“Alzheimer’s ‘Miracle Cure’ Discovered — Your Key to an Untapped $189 Billion Market”

By Travis Johnson, Stock Gumshoe, July 21, 2011

This is all hush-hush, you understand — I’m taking terrible risks by just writing to you today.

And my intrepid readers, members of the resistance, have also pushed the limits in sharing this news. The ad makes this very clear — it came with the subject line, “WARNING! Do Not Share, Do Not Forward”

But they did, my friends — that’s just how hard the mighty Gumshoe readers fight to make sure that profitable (maybe) information can reach our greedy little fists. One of them included this terse message:

“I have forwarded this message in defiance of instructions; please do not report me to Louis Navellier.”

Have no worries, my friends — your secret is safe with the Gumshoe.

And yes, that’s who is pitching this ad our way: Louis Navellier. He’s doing so — and, of course, using the silly language to make us feel like secret agents — in order to get new subscribers to one of his less expensive newsletters, Blue Chip Growth (“on sale” for $100/year at the moment).

But still, when you tell me you’ve got an Alzheimer’s stock that might actually produce something to help those suffering from this disease … well, that catches my attention. Not just because I’m such a well-known humanitarian, but because curing Alzheimer’s would make the dollar bill signs spin through your eyeballs so fast that you’d likely faint. This is one of the huge unmet areas of pharmaceutical demand — which is why the search for an Alzheimer’s cure always finds investors, and, of course, why so many little biotech stocks have crashed and burned in the effort to develop new compounds for this disease.

So what’s our stock?

Here’s how Louis introduces it:

“Breaking News

Are you getting our free Daily Update
"reveal" emails? If not,
just click here...


“Alzheimer’s ‘Miracle Cure’ Discovered

“What You Need to Know about the BIGGEST Medical Secret of our Lifetime….

“Stage Set for Massive Run-UP

“—Patented drug on verge of ‘Double Blockbuster’ status… could claim top spot in TWO of world’s fastest-growing medical markets

“—New £100,000 grant awarded to verify results.”

That’s actually almost enough to feed into the Thinkolator, right there in the headline. But then Navellier gets into the details a bit more just to give us a chance to be double-dog sure of our results:

“I’ve been telling my growth-stock readers to buy a Danish pharma superstar since June 2010…

“Even today, with its diabetes ‘miracle drug’ posting a 191% sales surge in the latest quarter alone…

“And with company officials predicting blockbuster sales of $1 billion by December…

“It’s small beans compared to what may lie just ahead for us.

“You see, while almost no one was looking, a German-born scientist discovered ‘promising indications’ that this very same diabetes drug also triggers brain cell growth and protects memory formation!

“In fact, Alzheimer’s Research U.K. is so impressed that they awarded his team a £99,221 grant to further their research.”

OK, so I could bore you with more of Louis’ blather — but, frankly, I’m likely to spit out so much of that myself that it seems unfair. So I’ll just take that abundant pile of clues, puree them nicely, pour ’em right into the Thinkolator, five minutes of processing and out the other side comes a delightful Jell-o mold of …

Novo Nordisk (NVO for the US ADR, the home trading is done in Copenhagen at NOVO, but the ADR is huge and liquid for this mega-cap company)

Yes, this is a “blue chip” company, per the focus of Navellier’s newsletter — it’s a $70 billion market cap global healthcare colossus that happens to be headquartered in Denmark.

And it’s not just that Novo Nordisk has a diabetes “Miracle Cure” (that’s arguable — there are a lot of competing products), but they are really a diabetes company, the vast majority of their sales come from various diabetes treatments and from insulin and insulin delivery systems. They do have other drugs in their pharma pipeline, including treatments for obesity and hemophilia that are fairly advanced, and several hormanal treatments (hormone replacement and growth hormontes), but most of them are either focused on diabetes or its side effects, or are diabetes drugs that they’re testing to see how they work on other diseases.

Which is the case with what Navellier is teasing here — he’s talking about their latest diabetes drug to get FDA approval (last year, I think), liraglutide — brand name Victoza.

And Victoza seems to be doing quite well — this is an injectable diabetes drug, and part of the appeal for diabetes treatments is decreasing the number of injections required. The previous standard drug, Byetta, requires two injections a day, apparently, and Victoza works with just one … and there are also competing drugs looking for approval that are oral, which is obviously more appealing if the drug works for you, or injectable less often (there’s a weekly version of Byetta called Bydureon from Eli Lilly and Amylin that is possibly going to get approved next year — they had a surprising delay from the FDA last Fall). Some of the next generation oral diabetes drugs have had troubles, too, so the competitive landscape seems to be very fluid but there seems to be quite a bit of demand for Victoza, at least so far.

And yes, it is being studied for Alzheimer’s — though to say that it’s a billion-dollar opportunity just now is probably a bit ambitious, it’s not that they’re entering phase III trials or anything — they’re just starting to study the drug for Alzheimer’s, thanks to that grant in the UK, and the general rule about Alzheimer’s drugs is that they have a very, very slow approval process. This is, after all, the brain we’re talking about, and a disease that we still don’t really understand very well.

There may be cause for optimism because it’s a drug that’s already considered pretty safe and in heavy usage, so by the time we learn anything about the impact on Alzheimer’s, if any, perhaps Victoza will have had so much use that it will be easy to add indications to the label without safety fears, I have no idea. Regardless, I wouldn’t expect Alzheimer’s news next week.

Novo Nordisk is, as I said, a big company — it takes big things to move the stock price in any abrupt fashion. The far bigger trend, I’d argue, is the continuing rapid increase in diabetes in the western world, and the likelihood that as emerging market middle classes follow our dietary path they’ll find the same fate — NVO’s core market is growing and shows no sign of stopping growth, and they’re close to being a “pure play” on diabetes … which is why they’re not cheap like many of the other big pharmaceutical companies are, they trade at a trailing PE of about 25 and a forward estimated PE of 19, with analysts expecting 15% annual growth in earnings for the next five years (how would they know? They don’t, it’s somewhere between a forecast and a guess).

The yield is also paltry compared to competitors like Pfizer (PFE), Eli Lilly (LLY) or Novartis (NVS), which have dividend yields ranging from 3-5% — but those stocks have also been flat or down somewhat over the last five years, while NVO has risen some 300%, so there’s a reason that it’s more expensive. One reason is that their strong recurring businesses in insulin and diabetes management don’t necessarily face the same kind of generic competition and “patent cliff” concerns as many blockbuster-dependent pharmas, though NVO does still have those same concerns to an (arguably) lesser degree.

So … are you ready to buy into this “double blockbuster?” Louis Navellier loves growth companies, so it’s not surprising to see him embrace a stock that is priced for growth — is it a good prescription for your portfolio? Let us know with a comment below.


guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

38 Comments
Inline Feedbacks
View all comments
A REISNER
Member
A REISNER
July 31, 2011 1:57 pm

ANOTHER PITCH TO SUBSCRIBE TO HI YIELD WEALTH

THE 8.2% MANHATTAN BANK.

THANKS

K. Shonk
Guest
K. Shonk
August 1, 2011 2:45 am

You can give yourself Alzheirmers very easily. All your have to do is inject your brain with nitrosamines, which is very easily done. All you have to do is eat a roasted hot dog or sausgage link ccotaining niitrates or nitrates. Roasting packaged meat products containing nitrates r nitrites is all that is needed to produce sufficient nitrosamines that ingesting them once a wekk over a 20 -40 year period to produce Alzheimer's in a large percentage of the population as the popultaton ages. This effect of nitrosamines was recently (2010) discovered by a researcher at Braown University. Don't want Alzheimer's, eliminate nitrosamines and fluoritde from your diet.

Add a Topic
5198
K. Shonk
Guest
K. Shonk
August 15, 2011 7:07 pm

The etiology of Alzheimers has recently been delineated. The disease is a consquence of brain inflamation that never shuts off. The causes are multiple and are the same as that for autism in the young, and involves continual activation of the brain's immune system cells and collateral damage to functioning brain cells. Excessive vaccinations are one very common trigger. For the details, watch the video lecture by Dr. Blaylock which can be accessed at: http://articles.mercola.com/sites/articles/archiv

K. Shonk
Guest
K. Shonk
August 15, 2011 7:09 pm
lacertus
Guest
lacertus
August 19, 2011 2:45 pm

Good lord, there's more psuedoscientific crap in these comments than you could shake a stick at without developing tennis elbow!

forpatients
Guest
forpatients
October 15, 2011 2:20 pm

Prevention best for disease, but virtually all (from arthritis, autism and Crohn’s disease to fibromyalgia to heart disease to cancer and diabetes) can be mitigated/reversed by natural means. Inflammation is correlated with diseases of aging. MDs in Canada and France are PAID to keep their patients healthy. I LOVE working abroad!
For Alzheimer’s, the drug Namenda blocks one pathway that leads to it. Lithium orotate/aspartate (NOT the lithium chloride for bipolar syndrome) blocks SIX pathways leading to Alzheimer’s disease. Price differential: about $4-5 for Namenda, per day, vs about 25 cents/day for over-the-counter lithium.
Absolutely agree with the “practical” medicine comments. We provide patients and physicians, worldwide, with information to help prevent/reverse disease, relying on world experts as consultants. Recently: an Austrailian patient wrote in – TESTS NOW ALL CLEAR – reversed an autoimmune disorder, Sjogren’s disease. Wednesday, a feisty 90 year old from Florida with bladder cancer said she stopped bleeding a month ago, and her oncologist told her not to bother to come see him until December. Motivated women in their 80’s reversed their pancreatic cancer. A 30-something from California reversed his brain tumor. Diabetes type 2 should be reversable in a matter of weeks. Patienrs should be able to reverse cancer without surgery, chemo (chemo destroys the immune system), or radiation. Detoxify on a continual basis, get the immune system tested and corrected, get oxygenated (hospitals in Russia, Malaysia and India advertise oxygen therapies), and eat properly. One MD detoxifies his patients once/week for 20 weeks, and then monthly, for life. NOT ONE has had a heart attack in 20 years. The US cannot afford “business as usual” aka the PROFIT MOTIVE when it comes to health care. The US spends twice as much on healthcare, per person, than any other country, yet we rank #63 in health care efficiency, per the World Health Organization. The only way to change things: one signed, FAXED letter to a member of Congress = 25,000 votes. Email = only 10 votes. Congresspeople track phone calls, emails, and mail EVERY DAY. Six letters from constituents usually trumps any lobbyist. At any given time, there are five TIMES as many drug company lobbyists on Capitol Hill as there are members of Congress – SIX times as many during the “Obamacare” effort. “Overhead” in Europe = 7%, in Japan, 2%, in the USA, > 30%. In democratic Scandinavia, the ballot lists categories and subcategories of what people pay their taxes for. Voters decide to pay more, less, or about the same – education/transportation/recreation/healthcare, etc? Politicians are an afterthought. They either do what the voters tell, them, or they retire/are booted out the next election. As one Swedish voter said, “We may pay high taxes, but we know what we pay for. “

Add a Topic
5564
Add a Topic
3397
Add a Topic
4154
SAGE
Guest
October 16, 2011 7:20 pm

The evidence is becoming incontrovetible that the RIGHT natural substances – the chemistry of them–supports the body’s strong energy to heal itself. The poisonous
pharmaceuticals are (thankfully by law) required to publish the possible side effects with prescriptions and also to announce them on the TV ads. Just read those, and listen to he disclaimers with the TV ads, and you get a very rapid and shocking grasp of the danger you put yourself in by taking them!

JOSEPH VANDERMARK
July 12, 2013 10:43 am

THERE is ACURE FOR ALZHEIMERS. Go to K STREET FINANCIAL, and read about it. The stock is AVXL .

Add a Topic
5971